or Try an Advanced Search...

    Technical Analysis for BCAB - BioAtla, Inc.

    Grade Last Price % Change Price Change
    C 2.09 8.85% 0.17
    BCAB closed up 8.85 percent on Friday, November 1, 2024, on 43 percent of normal volume.
    Earnings due: Nov 7
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Up
    Historical BCAB trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    180 Bullish Setup Bullish Swing Setup 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    BB Squeeze Started Range Contraction 0.00%
    Fell Below 20 DMA Bearish 8.85%
    Crossed Above 20 DMA Bullish 3.47%
    Inside Day Range Contraction 3.47%
    Fell Below 20 DMA Bearish 3.98%
    20 DMA Support Bullish 0.00%
    Up 3 Days in a Row Strength 0.00%
    Older End-of-Day Signals for BCAB ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 20 hours ago
    20 DMA Resistance about 22 hours ago
    60 Minute Opening Range Breakout about 23 hours ago
    Up 5% about 23 hours ago
    Rose Above 20 DMA about 23 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    BCAB Chart by TradingView
    Basic chart:

    Profile

    BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Clinical Medicine Drugs Health Care Tumor Cancer Immunotherapy Monoclonal Antibodies Non Small Cell Lung Cancer Melanoma Small Cell Lung Cancer Targeted Therapy Hepatocellular Carcinoma Bladder Cancer NSCLC Non Small Cell Lung Carcinoma Renal Cell Carcinoma Cervical Cancer Gastric Cancer

    Is BCAB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 31 BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024
    Oct 30 BioAtla, Inc. (NASDAQ:BCAB) has caught the attention of institutional investors who hold a sizeable 39% stake
    Oct 20 BioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading Into 2025
    Oct 9 BioAtla Inc (BCAB) Q2 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges
    Oct 9 'Big Short' Investor Michael Burry's China Bet Pays Off As Top Picks Surge Nearly 60% In 2 Months
    Oct 8 BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy
    Oct 7 BioAtla: Numerous Catalysts Coming In Q4
    Oct 4 BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
    Oct 1 BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
    Sep 23 BioAtla out-licenses BA3362 to Context Therapeutics
    See more BCAB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.02
    52 Week Low 1.14
    Average Volume 1,105,056
    200-Day Moving Average 2.14
    50-Day Moving Average 1.87
    20-Day Moving Average 1.99
    10-Day Moving Average 1.98
    Average True Range 0.15
    RSI (14) 57.26
    ADX 30.88
    +DI 22.85
    -DI 11.26
    Chandelier Exit (Long, 3 ATRs) 1.95
    Chandelier Exit (Short, 3 ATRs) 2.29
    Upper Bollinger Bands 2.13
    Lower Bollinger Band 1.84
    Percent B (%b) 0.85
    BandWidth 14.92
    MACD Line 0.04
    MACD Signal Line 0.04
    MACD Histogram -0.0002
    Fundamentals Value
    Market Cap 100.19 Million
    Num Shares 47.9 Million
    EPS -2.65
    Price-to-Earnings (P/E) Ratio -0.79
    Price-to-Sales 989.22
    Price-to-Book 1.47
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.33
    Resistance 3 (R3) 2.31 2.20 2.29
    Resistance 2 (R2) 2.20 2.14 2.22 2.28
    Resistance 1 (R1) 2.15 2.10 2.18 2.17 2.26
    Pivot Point 2.04 2.04 2.06 2.06 2.04
    Support 1 (S1) 1.99 1.98 2.02 2.01 1.92
    Support 2 (S2) 1.88 1.94 1.90 1.90
    Support 3 (S3) 1.83 1.88 1.89
    Support 4 (S4) 1.85